1. Introduction {#sec1}
===============

Colorectal cancer (CRC) is among the most frequently diagnosed cancers in the United States (US) \[[@B1]\]. In 2018, an estimated 140,250 Americans will be diagnosed with CRC and 50,630 individuals will die from the disease \[[@B2]\]. Although morbidity and mortality in CRC are reduced by high-quality healthcare and healthy lifestyles, the 5-year overall survival (OS) rates after initial diagnosis remain at 67% for patients with rectal cancer and 64% for patients with colon cancer \[[@B1]\]. Furthermore, CRC survivors have a high risk of cancer recurrence \[[@B3], [@B4]\] and secondary tumors, particularly in the digestive system \[[@B5]\].

The classic tumor, node, and metastasis (TNM) staging system is regarded as the standard prognostic parameter and forms the basis for treatment decisions in CRC \[[@B6]\]. However, since the TNM system fails to reflect the intrinsic biological heterogeneity of CRC, especially in patients with atypical early or occult metastases, only 40% of CRCs are diagnosed at an early stage and approximately 50% of recently diagnosed cases will progress to metastatic cancer \[[@B7]\]. In addition, the prognostic value of TNM in patients with CRC is suboptimal \[[@B8]\]. Currently, there is an unmet need for biomarkers that accurately predict CRC progression, metastasis, and treatment outcomes \[[@B9]\].

In recent years, increasing attention has been given to the role of mucins (MUC) in the pathogenesis of cancer. MUC are a family of high molecular weight glycosylated proteins \[[@B10]\], which have a highly polymorphic tandem repeat in the central region \[[@B11]\]. At present, approximately 20 MUC have been identified. These can be divided into two major subfamilies, secreting gel-type mucins and transmembrane mucins, according to their structure and function \[[@B12]\]. MUC are usually expressed on the apical surfaces of normal glandular epithelial cells and luminal epithelial cells and have key functions in immunity, cell adhesion, and intracellular signaling \[[@B13]\]. Studies on the subcellular distribution of MUC and biochemical characteristics of malignant transformation and progression implicate MUC in tumorigenesis and metastasis \[[@B14]--[@B18]\], suggesting that abnormal MUC expression may be a predictive biomarker of CRC.

Evidence suggests that MUC expression is involved in the invasion and metastasis of various malignancies, including gallbladder cancer \[[@B19]\], breast cancer \[[@B20]\], ovarian cancer \[[@B21]\], gastric carcinoma \[[@B22], [@B23]\], pancreatic carcinoma \[[@B24]--[@B26]\], ampullary cancer \[[@B27], [@B28]\], lung cancer \[[@B16], [@B29]\], prostate cancer \[[@B30]\], renal cell carcinoma \[[@B31]\], and appendiceal carcinoma \[[@B32]\]. However, the prognostic value of MUC expression in CRC remains controversial \[[@B33]--[@B37]\]. To clarify the inconsistent findings from previously published studies investigating the role of MUC in CRC, this meta-analysis was conducted to assess the association between MUC expression levels and prognosis in CRC and investigate the associations between MUC expression levels and several CRC clinicopathological characteristics.

2. Materials and Methods {#sec2}
========================

This systematic review and meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline \[[@B38]\]. Basing on previously published studies, our study does not include any research with humans or animals, so ethical recognition and patient consent are not required.

2.1. Search Strategy {#sec2.1}
--------------------

Two review authors independently searched the PubMed, Embase, Cochrane Library, and Web of Science databases from inception through September 13, 2019. Keywords included ("mucins" OR "mucin" OR "MUC") AND ("colorectal cancer" OR "colorectal neoplasm" OR "colorectal tumor" OR "colonic cancer" OR "colon cancer" OR "rectal cancer" OR "CRC") AND ("prognostic "OR "prognosis" OR "outcome" OR "survival"). A manual search of the reference lists of relevant articles was performed. Searches were limited to articles published in English or Chinese language.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The inclusion criteria were (1) study design: cohort study; (2) population: patients with CRC; (3) parameter: MUC expression levels in CRC tissues; and (4) outcome: association between MUC expression levels in CRC tissues and prognosis.

The exclusion criteria were as follows: (1) duplicate publications; (2) in vitro or animal studies; (3) reviews, conference reports, meta-analyses, books, case reports, or letters; or (4) studies that reported insufficient data. When articles reported data from the same study, the most recent article was included.

2.3. Data Extraction {#sec2.3}
--------------------

Two review authors independently extracted data from the eligible studies, including the surname of the first author, year, country, sample size, patients\' mean age, MUC phenotype, antibody for MUC, cut-off value for MUC, frequency of high MUC expression, detection method, TNM stage, histologic type, mean tumor dimensions, median follow-up, and outcomes. Disagreements about data extraction were resolved by discussion with a third reviewer until consensus was reached.

2.4. Quality Assessment {#sec2.4}
-----------------------

Two review authors independently conducted an assessment of the methodological quality of included studies using the Newcastle Ottawa Scale (NOS) \[[@B39]\]. The NOS assessed the quality of the enrolled groups, the comparability and outcomes of the study populations, and study quality on a scale from 0 to 9 points, with ≥7 considered high-quality research.

Publication bias was evaluated using Egger\'s linear regression and Begg\'s rank correlation test \[[@B40]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analyses were performed using Review Manager, version 5.3 (Cochrane Collaboration, Copenhagen, Denmark) and STATA, version 12.0 (Stata Corporation, College Station, TX, USA). Survival analysis was performed according to Moher et al. \[[@B38]\]. Hazard ratios (HRs) were directly extracted from included studies, or digitized and extracted using Engauge Digitizer version 4.1 (<http://markummitchell.github.io/engauge-digitizer/>) software when prognostic information was plotted as a Kaplan-Meier curve \[[@B41]\]. Pooled HRs with corresponding 95% confidence intervals (CIs) were used to assess the association between MUC expression levels (low vs. high) in CRC tissues and OS or disease-free survival (DFS)/relapse-free survival (RFS). Odds ratios (ORs) with 95% CIs were used to assess the impact of MUC expression levels on clinicopathological characteristics.

Studies with significant heterogeneity were identified with the chi-squared test (*P* ≤ 0.10) and the inconsistency index (*I*^2^ ≥ 50%) \[[@B42]\]. When significant heterogeneity was found, a random effects model was adopted. Otherwise, a fixed effects model is used. Subgroup analyses stratified by MUC phenotype and metaregression analysis were performed to explore sources of heterogeneity. The likelihood of publication bias was assessed by Egger\'s linear regression and Begg\'s rank correlation test. Sensitivity analysis evaluated the robustness of the data by omitting one study at a time. *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Search Results {#sec3.1}
-------------------

A total of 1273 articles were identified from the electronic search of the databases, and 3 additional studies were obtained from the manual search of the reference lists of relevant articles. After excluding 492 duplicates, titles and abstracts were screened, and 726 studies that did not meet the inclusion criteria were excluded. The full text of 58 studies was retrieved for further review, and 8 articles that did not report an endpoint, 8 articles with insufficient data, and 9 conference abstracts were excluded. Finally, 33 observational studies \[[@B33]--[@B37], [@B43]--[@B70]\] were found eligible for inclusion in our review ([Figure 1](#fig1){ref-type="fig"}).

3.2. Characteristics of the Included Studies {#sec3.2}
--------------------------------------------

The characteristics of the included studies are shown in [Table 1](#tab1){ref-type="table"}. The 33 eligible studies were published between 1987 and 2019. The studies included a total of 6032 cases. The mean age of patients ranged from 54.3 to 72.0 years, and the median follow-up ranged from 18.0 to 116.0 months. All included studies evaluated the correlation between MUC expression levels in CRC tissues and prognosis. 31 studies evaluated MUC expression using immunohistochemistry (IHC), and 2 studies used reverse transcriptase polymerase chain reaction (qRT-PCR). Nine MUC phenotypes, determined by the expression of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC12, MUC16, MUC20, and sialomucin, were associated with prognosis in CRC. Various anti-MUC monoclonal antibodies were utilized to identify the MUC phenotypes, and each study applied a different cut-off point (low/high level) to assess MUC expression.

3.3. Methodological Quality {#sec3.3}
---------------------------

According to the NOS, all included studies were of high methodological quality (score ≥ 7) ([](#supplementary-material-1){ref-type="supplementary-material"}).

3.4. MUC Expression and Overall Survival in CRC {#sec3.4}
-----------------------------------------------

The association between MUC expression levels in CRC tissues and OS was investigated in 41 datasets from 30 articles; each dataset represented various MUC phenotypes. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and OS (HR = 1.15; 95% CI, 0.95--1.40; *P* = 0.14). There was evidence of significant heterogeneity between studies (*P* \< 0.00001, *I*^2^ = 75%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR = 1.50; 95% CI, 1.29--1.74; *P* \< 0.00001; *P* = 0.72, *I*^2^ = 0%) or a low level vs. a high level of MUC2 expression (HR = 1.56; 95% CI, 1.27--1.92; *P* \< 0.00001; *P* = 0.11, *I*^2^ = 36%) was associated with poor OS in patients with CRC. However, associations between the levels of MUC5AC (HR = 1.41; 95% CI, 0.84--2.35; *P* = 0.19; *P* = 0.0002, *I*^2^ = 75%), other MUC phenotypes (HR = 1.43; 95% CI, 0.91--2.26; *P* = 0.12; *P* \< 0.00001, *I*^2^ = 81%), and OS were not significant ([Figure 2](#fig2){ref-type="fig"}).

3.5. MUC Expression and Disease-Free Survival/Recurrence-Free Survival in CRC {#sec3.5}
-----------------------------------------------------------------------------

The association between MUC expression level in CRC tissues and DFS/RFS was investigated in 19 datasets from 11 articles. The meta-analysis demonstrated no association between combined MUC phenotype expression levels and DFS/RFS (HR = 0.98; 95% CI, 0.75--1.29; *P* = 0.90). There was evidence of significant heterogeneity between studies (*P* \< 0.00001, *I*^2^ = 70%). The source of the heterogeneity was investigated in a subgroup analysis stratified by specific MUC phenotype. The subgroup analysis demonstrated that a high level vs. a low level of MUC1 expression (HR = 1.99; 95% CI, 0.99--3.99; *P* = 0.05; *P* = 0.0001, *I*^2^ = 78%) or other MUC expression (HR = 2.09; 95% CI, 1.27--3.42; *P* = 0.003; *P* = 0.51, *I*^2^ = 0%) was associated with shorter DFS/RFS in patients with CRC. However, a high level vs. a low level of MUC5AC expression (HR = 0.56; 95% CI, 0.38--0.82; *P* = 0.003; *P* = 0.69, *I*^2^ = 0%) was associated with longer DFS/RFS and patients with a low level of MUC2 tumors showed better DFS/RFS than patients with a high level of MUC2 tumors (HR = 0.71; 95% CI, 0.49--1.04; *P* = 0.08; *P* = 0.0.009, *I*^2^ = 67%).([Figure 3](#fig3){ref-type="fig"}).

3.6. MUC Expression and CRC Clinicopathological Characteristics {#sec3.6}
---------------------------------------------------------------

The meta-analysis demonstrated no association between combined MUC phenotype expression levels and CRC clinicopathological characteristics. In all analyses, there was evidence of significant heterogeneity between studies. The source of the heterogeneity was investigated in subgroup analyses stratified by specific MUC phenotype ([Table 2](#tab2){ref-type="table"}).

A high level of MUC1 expression (III/IV vs. I/II: OR = 2.17, 95% CI = 1.31--3.59, *P* = 0.002) was associated with advanced tumor stage in patients with CRC than MUC2 expression (III/IV vs. I/II: OR = 0.52, 95% CI = 0.36--0.76, *P* = 0.0008), but the association between MUC5AC expression and tumor stage was not significant.

A high level of MUC1 expression (T3/T4 vs. T1/T2: OR = 1.79, 95% CI = 1.41--2.26, *P* \< 0.00001) was associated with deeper invasion in patients with CRC, but the association between MUC5AC and MUC2 expression and depth of invasion was not significant.

A high level of MUC1 expression (positive vs. negative: OR = 2.45, 95% CI = 1.38--4.35, *P* = 0.002) was associated with lymph node metastasis in patients with CRC than MUC2 expression (positive vs. negative: OR = 0.59, 95% CI = 0.47--0.73, *P* \< 0.00001), but the association between MUC5AC expression and lymph node metastasis was not significant.

A high level of MUC1 expression (positive vs. negative: OR = 0.79, 95% CI = 0.63--0.98, *P* = 0.03) was associated with rectum cancer. However, the elevated MUC2 expression (positive vs. negative: OR = 1.64, 95% CI = 1.01--2.67, *P* = 0.04) and MUC5AC expression (positive vs. negative: OR = 1.97, 95% CI = 1.48--2.62, *P* \< 0.00001) were associated with colon cancer.

A high level of MUC1 expression was associated with distant metastasis (positive vs. negative: OR = 2.47, 95% CI = 1.47--4.13, *P* = 0.0006) and lymphatic invasion (positive vs. negative: OR = 3.39, 95% CI = 1.69--9.14, *P* = 0.001) in patients with CRC. A high level of MUC2 expression was associated mucinous cancer (high vs. low: OR = 14.46, 95% CI = 1.71--121.97, *P* = 0.01) and low histological grade (3 vs. 1 and 2: OR = 0.75, 95% CI = 0.56--0.99, *P* = 0.04).

There were no associations between the expression levels of any MUC phenotypes and other clinicopathological characteristics, including gender or tumor size.

3.7. Sensitivity Analysis and Publication Bias {#sec3.7}
----------------------------------------------

Sensitivity analysis omitting one study at a time demonstrated the associations of MUC family members\' expression with OS ([Figure 4](#fig4){ref-type="fig"}) and DFS/RFS ([Figure 5](#fig5){ref-type="fig"}) in CRC were robust. Begg\'s rank correlation test and Egger\'s linear regression showed no publication bias among studies investigating OS ([Figure 6](#fig6){ref-type="fig"}) and DFS/RFS ([Figure 7](#fig7){ref-type="fig"}).

3.8. Metaregression {#sec3.8}
-------------------

Metaregression was performed to explore the factors influencing the association of MUC expression with OS and DFS/RFS in CRC. None of the covariates (cut-off value, antibody, TNM stage, country, and years) analyzed were identified as potential sources of heterogeneity ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

In this meta-analysis, we assessed the association between MUC expression levels in CRC tissues and prognosis and investigate the associations between MUC expression levels and several CRC clinicopathological characteristics. Interestingly, findings demonstrated no association between combined MUC phenotype expression levels in CRC tissues and prognosis. However, in subgroup analyses stratified by MUC phenotype, a high level of MUC1 expression was associated with poor OS and DFS/RFS, a high level of MUC2 expression was associated with improved OS and DFS/RFS, and a high level of MUC5AC was associated with improved DFS/RFS. Generally, heterogeneity between studies was significantly reduced in the subgroup analyses stratified by MUC phenotype. Meanwhile, meta-regression analysis revealed that antibody for MUC, cut-off value for MUC, TNM stage, and histologic type were not significant sources of heterogeneity.

However, importantly, several studies have shown a correlation between MUC expression and patient with various cancers. For example, a meta-analysis reported that MUC expression was significantly higher in patients with esophageal adenocarcinoma than in normal squamous esophageal mucosa \[[@B71]\]. The study by Lu et al. \[[@B72]\] also indicated that increased MUC expression was associated with worse OS and more detrimental clinicopathological outcomes in head and neck cancer patients. Overall, it is reasonable that the expression of MUC was associated with variable clinical outcomes in different tumors. These differences may be due to different mechanisms, pathways, and treatment options. An earlier meta-analysis have shown that abnormal expression of MUC in CRC tissues compared with healthy mucosa plays an important role in the pathogenesis and progression of CRC \[[@B73]\]. Several meta-analyses have explored the association between MUC expression and CRC clinicopathological characteristics \[[@B74]--[@B76]\]. Furthermore, compared with two earlier meta-analyses for various types of cancer by Xu et al. \[[@B77]\] and Huang et al. \[[@B78]\], the present analysis not only added additional 26 and 27 studies in colorectal cancer subtype but also examined the correlation between MUC expression and the clinicopathological factors of colorectal cancer.

The current study explored the association between MUC expression levels in CRC tissues and CRC clinicopathological characteristics. A high level of MUC1 expression was associated with CRC in the rectum, deeper invasion, lymph node metastasis, distant metastasis, advanced tumor stage, and lymphatic invasion. Elevated MUC2 expression was associated with CRC in the colon, shallower lesions, negative lymph node metastasis, early stage of tumor, mucinous carcinoma, and larger tumor size. MUC5AC was more easily expressed in colon cancer. These findings implicate MUC1 in mechanisms that promote tumor invasion, lymph node metastasis, high stage, lymphatic invasion, and poor survival in CRC, while MUC2 may have a protective role. A number of studies have demonstrated a unique role for MUC in proliferation, survival, metastasis, epithelial-mesenchymal transition, and antiapoptosis in tumors \[[@B13], [@B17], [@B79]--[@B82]\]. As a ligand of cell adhesion molecules, MUC 1 induces circulating tumor cells (CTCs) to adhere to endothelial cells or transport to distant sites, establishing secondary tumors \[[@B81]\]. MUC2 is major structural component of the inner mucus layer in the colon, which is impervious to bacteria and protects the colon epithelium. Decreased MUC2 expression allows bacteria to contact the epithelial surface, triggering inflammatory bowel disease, which can lead to colon cancer \[[@B83]\]. Studies characterizing the function of MUC5AC are scarce. Hoshi et al. \[[@B84]\] showed that MUC5AC protects pancreatic cancer cells from TRAIL-induced apoptosis, while other reports suggest that MUC5AC has no effect on cell growth, cell survival, proliferation, or morphology in vitro \[[@B85]\].

Findings from the current meta-analysis indicate MUC1 may be a biomarker of poor prognosis in CRC and suggest that combined detection of MUC1 and MUC2 should be used to accurately predict CRC progression, metastasis, and treatment outcomes. Understanding the association between MUC expression levels and metastasis in CRC may help clarify the risk of metastasis at the time of diagnosis in patients with CRC, especially in those patients without symptoms or signs of metastasis. Clinically, MUC detection is simple and easy to implement.

This study was associated with several limitations. First, HRs from some of the included studies were calculated from Kaplan-Meier curves, which may have influenced the robustness of our findings. Second, the lack of a standardized detection methods and antibodies to detect MUC status may have affected the accuracy of our results. Third, despite the use of subgroup analysis and meta-regression to identify potential sources of heterogeneity between studies, they may have been additional sources of heterogeneity that impacted our findings. Finally, the sample size was small, and results should be considered preliminary.

In conclusion, findings from the current study suggest that MUC1 and MUC2 expression levels in CRC tissues are associated with OS, DFS/RFS, tumor site, depth of invasion, lymph node metastasis, distant metastasis, tumor stage, histologic type, and lymphatic invasion. These results indicate that MUC status can be used to differentiate between normal cells and CRC cells and predict a patient\'s clinicopathological characteristics and prognosis. The clinical relevance of MUC regulation in CRC tissues remains to be elucidated in large well-designed cohort studies.
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###### 

Characteristics of the included studies.

  First author   Year   Country        Patient number   Detection method   Mean age (years)   Media follow-up (mounts)   Outcome   Mucins phenotype   Antibody                              Cut-off value (high level)   High MUC expression
  -------------- ------ -------------- ---------------- ------------------ ------------------ -------------------------- --------- ------------------ ------------------------------------- ---------------------------- ---------------------
  Adams          2009   Switzerland    938              IHC                70.5               128.0                      OS        MUC2               NR                                    PP \> 5%                     NR
  Al-Maghrabi    2019   Saudi Arabia   128              IHC                NR                 NR                         OS/DFS    MUC2               MRQ-18                                PP ≥ 25%                     36.7%
  Baldus         2000   Germany        264              IHC                64.8               NR                         OS        MUC1               NCL-MUC1                              PP \> 5%                     58.0%
  Baldus         2004   Germany        205              IHC                65.0               NR                         OS        MUC1               HMFG-2                                PP \> 35%                    49.8%
  Betge          2016   Germany        381              IHC                68.5               NR                         OS/DFS    MUC1               Ma695                                 PP \> 0%                     64.0%
                                                                                                                         MUC2      Ccp-58             PP \> 0%                              77.0%                        
                                                                                                                         MUC5AC    45M1               PP \> 0%                              48.9%                        
                                                                                                                         MUC6      MCN6.01            PP \> 0%                              28.7%                        
  Dawson         1987   UK             358              IHC                65.7               18.0                       OS        Sialomucin         High iron diamine-alcian blue         Blue staining                29.6%
  Diaz           2018   Spain          96               IHC                65.9               NR                         DFS       MUC1               Clone E29                             PP ≥ 50%                     46.0%
  Duncan         2007   UK             403              IHC                72.0               116.0                      OS        MUC1               Ma695                                 PP ≥ 30%                     31.5%
                                                                                                                         MUC3      1143/B7            PP ≥ 30%                              73.9%                        
  Elzagheid      2013   Libya          141              IHC                NR                 77.0                       OS/DFS    MUC2               MRQ-18                                PP \> 0%                     50.0%
  Hiraga         1998   Japan          100              IHC                62.7               80.0                       OS        MUC1               KL-6                                  PP \> 30%                    71.0%
  Imai           2013   Japan          250              IHC                66.9               NR                         OS/RFS    MUC2               Ccp-58                                PP ≥ 25%                     49.4%
                                                                                                                         MUC5AC    CLH2               PP ≥ 1%                               46.8%                        
  Ionescu        2014   Romania        39               qRT-PCR            66.0               NR                         OS        MUC12              NR                                    NR                           NR
  Kang           2011   Korea          229              IHC                NR                 108                        OS        MUC2               NR                                    Score ≥ 6                    24.2%
  Kasprzak       2018   Poland         34               IHC                NR                 NR                         OS        MUC1               Ma552                                 PP ≥ 2.57%                   100%
                                                                                                                         MUC2      Ccp-58             PP ≥ 4.97%                            100%                         
  Khanh          2013   Japan          206              IHC                NR                 NR                         OS/RFS    MUC1               Ma695                                 PP ≥ 25%                     62.6%
                                                                                                                         MUC2      Ccp-58             PP ≥ 50%                              32.5%                        
                                                                                                                         MUC4      1G8                PP ≥ 50%                              33.0%                        
                                                                                                                         MUC5AC    CLH2               PP ≥ 5%                               33.5%                        
  Kimura         2000   Japan          110              IHC                63.1               68.5                       OS        MUC1               KL-6                                  PP ≥ 30%                     69.1%
  Kocer          2002   Turkey         41               IHC                56.3               NR                         DFS       MUC5AC             45M1                                  ISS \> 0.1                   34.1%
  Kocer          2006   USA            30               IHC                59.0               39.0                       OS        MUC5AC             45M1                                  PP \> 10%                    60.0%
  Lennerz        2016   USA            33               IHC                58.0               51.2                       OS        MUC2               Ccp58                                 PP ≥ 10%                     84.0%
                                                                                                                         MUC5AC    CLH2               PP ≥ 10%                              45.0%                        
                                                                                                                         MUC6      CLH5               PP ≥ 10%                              0.0%                         
  Manne          2000   USA            166              IHC                65.3               NR                         OS        MUC1               DF3                                   SI ≥ 0.5                     39.8%
                                                                                                                         MUC2      Ccp58              SI ≥ 0.5                              80.7%                        
  Matsuda        2010   *Japan*        569              IHC                68.0               NR                         OS        MUC2               Anti-MUC2                             PP ≥ 10%                     65.0%
                                                                                                                         MUC5AC    Anti-MUC5          PP ≥ 10%                              15.1%                        
                                                                                                                         MUC6      Anti-MUC6          PP ≥ 10%                              1.9%                         
  Matsuyama      2010   Japan          100              qRT-PCR            65.1               27.0                       DFS       MUC12              Rabbit polyclonal antibody            NR                           NR
  Perez          2008   Brazil         35               IHC                62.2               NR                         OS/DFS    MUC1               Ma695                                 PP \> 10%                    20.0%
                                                                                                                         MUC2      Ccp-58             PP \> 10%                             65.7%                        
                                                                                                                         MUC5AC    CLH2               PP \> 10%                             22.9%                        
  Shanmugam      2010   USA            132              IHC                65.0               NR                         OS        MUC4               Clone 8G7                             ISS \> 2                     24.2%
  Sun            2018   China          118              IHC                54.3               57.0                       OS/DFS    MUC1               MXB Biotechnologies                   PP ≥ 10%                     14.4%
  Streppel       2012   USA            39               IHC                63.6               NR                         OS        MUC16              Monoclonal antibody                   PP \> 0%                     64.1%
  Wang           2016   China          81               IHC                63.5               NR                         OS        MUC1               ZM-0391                               ISS \> 1                     53.1%
  Wang           2017   China          139              IHC                NR                 NR                         OS        MUC2               NCL-MUC2                              PP \> 20%                    48.2%
                                                                                                                         MUC5AC    NCL-MUC5           PP \> 20%                             28.1%                        
  Xiao           2013   China          150              IHC                55.0               NR                         OS/DFS    MUC20              Mouse antihuman polyclonal antibody   ISS \> 2                     60.7%
  You            2006   China          203              IHC                NR                 111.9                      OS        MUC1               Ma695                                 IRS ≥ 2                      40.7%
  Yu             2007   China          150              IHC                57.5               NR                         OS        MUC1               Ma695                                 ISS ≥ 2                      45.3%
                                                                                                                         MUC2      Ccp-58             ISS ≥ 2                               52.6%                        
                                                                                                                         MUC5AC    45M1               ISS ≥ 2                               44.0%                        
  Zhang          2008   Japan          77               IHC                64.9               NR                         OS        MUC1               KL-6                                  SI (positive)                55.8%
  Zwenger        2014   Argentina      90               IHC                NR                 NR                         OS        MUC1               HMFG1                                 Score \> 0                   94.0%
                                                                                                                         MUC2      H300               Score \> 0                            52.4%                        

NR: not reported; RT-PCR: reverse transcriptase polymerase chain reaction; IHC: immunohistochemistry; SI: staining intensity; PP: positive cell percentage; immunostaining score (ISS): PP^∗^SI (while groups I and II (absent and low) were considered negative expression).

###### 

Meta-analysis of the correlation between MUC expression and clinicopathological factors of colorectal cancer.

  Clinicopathological parameter         Mucins phenotype   No. of studies        OR (95% CI)        Analysis model   Test for overall effect   Heterogeneity            
  ------------------------------------- ------------------ --------------------- ------------------ ---------------- ------------------------- --------------- -------- -----------
  TNM stage (III/IV vs. I/II)           MUC1               11                    2.17 (1.31-3.59)   Random           3.03                      0.002           83       \<0.00001
  MUC2                                  7                  0.52 (0.36-0.76)      Random             3.35             0.0008                    52              0.05     
  MUC5AC                                8                  1.00 (0.67-1.49)      Random             0.01             0.99                      55              0.03     
                                                                                                                                                                        
  Depth of invasion (T3/T4 vs. T1/T2)   MUC1               11                    1.79 (1.41-2.26)   Fixed            4.86                      \<0.00001       40       0.08
  MUC2                                  6                  0.65 (0.37-1.13)      Random             1.53             0.13                      63              0.02     
  MUC5AC                                4                  0.64 (0.35-1.18)      Random             1.42             0.15                      61              0.05     
                                                                                                                                                                        
  Lymph node metastasis (+ vs. -)       MUC1               10                    2.45 (1.38-4.35)   Random           3.07                      0.002           81       \<0.00001
  MUC2                                  8                  0.59 (0.47-0.73)      Fixed              4.64             \<0.00001                 48              0.06     
  MUC5AC                                7                  1.07 (0.67-1.72)      Random             0.29             0.77                      67              0.006    
                                                                                                                                                                        
  Tumor site (colon vs. rectum)         MUC1               7                     0.79 (0.63-0.98)   Fixed            2.12                      0.03            0        0.63
  MUC2                                  5                  1.64 (1.01-2.67)      Random             2.02             0.04                      55              0.06     
  MUC5AC                                6                  1.97 (1.48-2.62)      Fixed              4.63             \<0.00001                 49              0.08     
                                                                                                                                                                        
  Distant metastasis (+ vs. -)          MUC1               3                     2.47 (1.47-4.13)   Fixed            3.43                      0.0006          49       0.14
  MUC2                                  3                  0.83 (0.48-1.41)      Fixed              0.70             0.49                      0               0.61     
  MUC5AC                                2                  0.86 (0.15-4.87)      Random             0.17             0.87                      73              0.06     
                                                                                                                                                                        
  Lymphatic invasion (+ vs. -)          MUC1               5                     3.39 (1.69-9.14)   Random           3.19                      0.001           72       0.007
  MUC2                                  3                  0.53 (0.27-1.03)      Random             1.88             0.06                      60              0.08     
  MUC5AC                                4                  0.76 (0.55-1.05)      Fixed              1.64             0.10                      20              0.29     
                                                                                                                                                                        
  Mucinous component (high vs. low)     MUC1               7                     0.71 (0.42-1.19)   Random           1.31                      0.19            59       0.02
  MUC2                                  2                  14.46 (1.71-121.97)   Random             2.46             0.01                      59              0.12     
  MUC5AC                                3                  1.41 (0.85-2.34)      Fixed              1.32             0.19                      0               0.62     
                                                                                                                                                                        
  Gender (male vs. female)              MUC1               7                     1.10 (0.86-1.41)   Fixed            0.77                      0.44            0        0.75
  MUC2                                  7                  0.87 (0.68-1.12)      Fixed              1.07             0.29                      8               0.29     
  MUC5AC                                6                  0.93 (0.69-1.24)      Random             \<0.00001        1.00                      55              0.005    
                                                                                                                                                                        
  Tumor size (large vs. small)          MUC1               4                     0.77 (0.53-1.12)   Fixed            1.38                      0.17            19       0.30
  MUC2                                  2                  0.70 (0.47-1.05)      Fixed              1.73             0.08                      0               0.39     
  MUC5AC                                2                  0.80 (0.48-1.32)      Fixed              0.87             0.38                      0               0.41     
                                                                                                                                                                        
  Histological grade (3 vs. 1 and 2)    MUC1               12                    1.39 (0.87-2.21)   Random           1.39                      0.16            66       0.0007
  MUC2                                  7                  0.75 (0.56-0.99)      Fixed              2.02             0.04                      44              0.10     
  MUC5AC                                5                  1.44 (0.70-2.97)      Random             0.99             0.32                      79              0.0007   

RR: risk ratio; Random: random effects model; Fixed: fixed.

###### 

Results of meta-regression analysis exploring the source of heterogeneity with OS and DFS/RFS.

  Mucins phenotype   Covariates   Univariate analysis (OS)   Univariate analysis (DFS)                             
  ------------------ ------------ -------------------------- --------------------------- -------- -------- ------- -------
  MUC1               Antibody     0.055                      0.087                       0.538    -0.142   0.882   0.883
  Cut-off value      0.0297       0.032                      0.369                       0.155    0.295    0.635   
  TNM stage          0.365        0.324                      0.281                       0.773    1.106    0.535   
  Country            0.048        0.462                      0.323                       0.155    0.295    0.635   
  Year               -0.001       0.014                      0.964                       -0.077   0.115    0.552   
                                                                                                                   
  MUC2               Antibody     -0.204                     0.215                       0.367    0.550    0.252   0.094
  Cut-off value      -0.027       0.043                      0.552                       -0.030   0.221    0.898   
  TNM stage          -0.309       0.124                      0.054                       -0.270   0.838    0.763   
  Country            0.007        0.048                      0.891                       0.180    0.050    0.023   
  Year               0.036        0.030                      0.264                       0.108    0.030    0.022   
                                                                                                                   
  MUC5AC             Antibody     0.464                      0.269                       0.135    -0.139   0.434   0.769
  Cut-off value      0.187        0.158                      0.282                       -0.248   0.193    0.288   
  TNM stage          0.923        0.211                      0.055                       -0.652   0.961    0.546   
  Country            0.250        0.240                      0.339                       -0.379   0.293    0.287   
  Year               0.135        0.073                      0.859                       0.102    0.069    0.236   

[^1]: Academic Editor: Haruhiko Sugimura
